|19th October 2020||John Gordon Freund||190,053||Open or private sale||$22.00||$4,181,166.00|
|15th October 2020||Shirley R. Kuhlmann||7,060||Open or private sale||$20.82||$146,989.20|
|30th September 2020||Theodore R Schroeder||1,211||Payment by withholding||$0.53||$645.46|
|24th September 2020||Rita J. Balice Gordon||5,027||Grant/award etc.||$0.00|
|18th September 2020||John Gordon Freund||400,000||Open or private sale||$12.00||$4,800,000.00|
|16th September 2020||Shirley R. Kuhlmann||734||Payment by withholding||$19.33||$14,188.22|
|11th September 2020||John Gordon Freund||500,000||Open or private sale||$10.00||$5,000,000.00|
|31st August 2020||Theodore R Schroeder||1,211||Payment by withholding||$0.62||$750.09|
|19th August 2020||John Gordon Freund||500,000||Open or private sale||$8.72||$4,360,000.00|
|11th August 2020||Michael Thomas Heffernan||13,071||Open or private sale||$19.13||$250,048.23|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. Its products include Xtampza ER, Nucynta ER and NucyNTa IR. The company was founded by Michael Thomas Heffernan in 2003.